top of page
  • Recruiting

NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With RRMM

Updated: Jun 22, 2022

NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

KPd

Kpd

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov Identifier: NCT01665794


Sponsor:

University of Chicago


Collaborators:

National Cancer Institute (NCI)

Multiple Myeloma Research Foundation

MMRF


The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete.


This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.

 

ClinicalTrials.gov Identifier: NCT01464034


Official Title: Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

First Posted: August 15, 2012


 


 

Drug: Pomalidomide

Drug: Carfilzomib

Drug: dexamethasone

Drug: Daratumumab

 

Locations

United States, Illinois

United States, Michigan

United States, Tennessee

Canada, Ontario






Comentarios


Posts Archive
bottom of page